Armata’s phage product candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata’s lead product candidate, AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. Armata is also developing and advancing a broad pipeline of proprietary synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed with Merck.
|Pathogen||Indications||Discovery||Preclinical||Phase 1||Phase 2|
|Phase 1/2 |